Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

BACKGROUND: The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3(rd )or later-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lièvre, Astrid, Samalin, Emmanuelle, Mitry, Emmanuel, Assenat, Eric, Boyer-Gestin, Christine, Lepère, Céline, Bachet, Jean-Baptiste, Portales, Fabienne, Vaillant, Jean-Nicolas, Ychou, Marc, Rougier, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761407/
https://ncbi.nlm.nih.gov/pubmed/19785749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-347
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados